Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
about
Dosing of antibacterial agents in obese adults: does one size fit all?Sublethal concentrations of carbapenems alter cell morphology and genomic expression of Klebsiella pneumoniae biofilmsSynergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.Modeling approach to characterize intraocular doripenem pharmacokinetics after intravenous administration to rabbits, with tentative extrapolation to humansThe combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelPopulation Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.Pharmacodynamic variability beyond that explained by MICs.Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaApplications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.Interethnic differences in pharmacokinetics of antibacterials.Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery.Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
P2860
Q30362353-5CA2F154-C461-450A-96AF-32B6AA2F7CA7Q35076815-D5C10302-9D37-4502-851B-D8F398583CEEQ35598403-9F0201FF-B0EF-4DD2-88AA-45D26E6E190EQ36086333-B94EDBB8-3FA8-48F0-A680-7510396785A5Q36276852-13EA96EE-D4C9-4282-9384-459E691F8774Q36438971-CED4E233-2AD4-4F37-B7CA-CC6F07DAB898Q36757639-75D80671-52B1-441D-B431-DBFB355CD1EFQ36887819-35B51E3D-C0FF-4196-92EA-070B921F22D9Q37259653-A91850ED-4F09-4794-A64C-5FED63C65D21Q37538602-008C4BED-141B-4FF2-93CD-C0B63475950FQ38073197-37ACF4A2-E46C-47DA-BA69-9F94B540A175Q38266806-924A7F42-864F-41C7-A5CC-3E7A475E61C6Q38405565-305438FF-41FF-4489-8A18-AB901BC92E57Q40749626-BBF74D8B-8733-498C-8EAA-81073A76BAEBQ42257467-62B90A54-3468-4003-A5F9-ED1A608C8934Q42632207-6EAA043F-93B5-4A7A-B68F-1FF74B2C5CDFQ43516275-83E9F3E5-4E70-404B-BC0D-143CD73BEAF1Q46762411-E6828A99-3159-4C0E-822A-F26A957E701CQ54561986-7855C109-C633-40BA-9410-439D7590A380
P2860
Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Population pharmacokinetics of ...... with critically ill patients.
@ast
Population pharmacokinetics of ...... with critically ill patients.
@en
Population pharmacokinetics of ...... with critically ill patients.
@nl
type
label
Population pharmacokinetics of ...... with critically ill patients.
@ast
Population pharmacokinetics of ...... with critically ill patients.
@en
Population pharmacokinetics of ...... with critically ill patients.
@nl
prefLabel
Population pharmacokinetics of ...... with critically ill patients.
@ast
Population pharmacokinetics of ...... with critically ill patients.
@en
Population pharmacokinetics of ...... with critically ill patients.
@nl
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... with critically ill patients.
@en
P2093
Mahesh N Samtani
Partha Nandy
Rachel Lin
P2860
P304
P356
10.1128/AAC.01649-09
P407
P577
2010-04-12T00:00:00Z